Literature DB >> 2824522

Prognostic factors in non-small cell lung cancer: multiregression analysis in the National Cancer Center Hospital (Japan).

M Sakurai1, T Shinkai, K Eguchi, Y Sasaki, T Tamura, K Miura, Y Fujiwara, A Otsu, N Horiuchi, H Nakano.   

Abstract

A total of 190 patients with unresectable non-small cell lung cancer (NSCLC) were analyzed retrospectively using eight pretreatment and three treatment-related prognostic factors in terms of influence on survival. All the patients received chemotherapy with or without chest irradiation, according to the protocol of phase II or phase III trials of the National Cancer Center Hospital Tokyo between April 1980 and December 1985. The eight pretreatment factors selected were performance status, sex, stage, age, histology, and metastasis to brain, bone or, liver. Three treatment-related factors were radiation therapy to the primary site, response to chemotherapy, and treatment period, before or after clinical administration of cis-diamminedichloroplatinum (II) (CDDP). Of the 190 patients, 71 (37.4%) were alive for more than 1 year, but only 17 patients (8.9%) survived 2 years after the initiation of chemotherapy. By univariate analysis, performance status 0-1, female, no metastasis to bone or liver, response to chemotherapy, and treatment period after CDDP were considered to be favorable prognostic factors. By multiregression analysis, performance status, sex, and treatment period after CDDP proved to be important factors for long-term survival. Consideration of these prognostic factors could enable the results of chemotherapy to be more accurately evaluated, and stratification of patients with advanced NSCLC based on performance status and sex before entry into a randomized controlled trial is recommended.

Entities:  

Mesh:

Year:  1987        PMID: 2824522     DOI: 10.1007/BF00390866

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  15 in total

1.  Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy.

Authors:  J P O'Connell; M G Kris; R J Gralla; S Groshen; A Trust; J J Fiore; D P Kelsen; R T Heelan; R B Golbey
Journal:  J Clin Oncol       Date:  1986-11       Impact factor: 44.544

2.  Effect of peplomycin plus carbazilquinone and mitomycin on non-small cell carcinoma of the lung.

Authors:  N Saijo; E Shimizu; K Eguchi; T Shinkai; K Tominaga; M Shibuya; Z Shimabukuro; H Niitani; A Hoshi
Journal:  Cancer Treat Rep       Date:  1983-04

3.  Illusion and reality: practical pitfalls in interpreting clinical trials.

Authors:  E Glatstein; R W Makuch
Journal:  J Clin Oncol       Date:  1984-05       Impact factor: 44.544

4.  Randomized trial of three combinations of cisplatin with vindesine and/or VP-16-213 in the treatment of advanced non-small-cell lung cancer.

Authors:  H M Dhingra; M Valdivieso; D T Carr; D F Chiuten; P Farha; W K Murphy; G Spitzer; T Umsawasdi
Journal:  J Clin Oncol       Date:  1985-02       Impact factor: 44.544

5.  Cisplatin and vindesine combination chemotherapy for non-small cell lung cancer: a randomized trial comparing two dosages of cisplatin.

Authors:  T Shinkai; N Saijo; K Eguchi; Y Sasaki; K Tominaga; M Sakurai; J Suga; H Miyaoka; T Sano; N Keicho
Journal:  Jpn J Cancer Res       Date:  1986-08

6.  A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer.

Authors:  J C Ruckdeschel; D M Finkelstein; D S Ettinger; R H Creech; B A Mason; R A Joss; S Vogl
Journal:  J Clin Oncol       Date:  1986-01       Impact factor: 44.544

7.  Comparison of vindesine plus cisplatin or vindesine plus mitomycin in the treatment of advanced non-small cell lung cancer.

Authors:  T Shinkai; N Saijo; K Tominaga; K Eguchi; E Shimizu; Y Sasaki; J Fujita; H Futami
Journal:  Cancer Treat Rep       Date:  1985-09

8.  Prognostic factors for survival in patients with inoperable lung cancer.

Authors:  K E Stanley
Journal:  J Natl Cancer Inst       Date:  1980-07       Impact factor: 13.506

9.  Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: A randomized trial investigating two dosage schedules.

Authors:  R J Gralla; E S Casper; D P Kelsen; D W Braun; M E Dukeman; N Martini; C W Young; R B Golbey
Journal:  Ann Intern Med       Date:  1981-10       Impact factor: 25.391

10.  Combination chemotherapy with cisplatin and etoposide in bronchogenic squamous cell carcinoma and adenocarcinoma. A study by the EORTC lung cancer working party (Belgium).

Authors:  E Longeval; J Klastersky
Journal:  Cancer       Date:  1982-12-15       Impact factor: 6.860

View more
  5 in total

1.  Specific organ metastases and survival in metastatic non-small-cell lung cancer.

Authors:  Tomohiro Tamura; Koichi Kurishima; Kensuke Nakazawa; Katsunori Kagohashi; Hiroichi Ishikawa; Hiroaki Satoh; Nobuyuki Hizawa
Journal:  Mol Clin Oncol       Date:  2014-09-04

2.  Phase II study of 5-day continuous infusion of cis-diamminedichloroplatinum(II) in the treatment of non-small-cell lung cancer.

Authors:  Y Saito; K Mori; K Tominaga; K Yokoi; N Miyazawa
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

3.  Pretreatment clinical prognostic factors in patients with stage IV non-small cell lung cancer (NSCLC) treated with chemotherapy.

Authors:  Branislav Jeremic; Biljana Milicic; Aleksandar Dagovic; Jasna Aleksandrovic; Nebojsa Nikolic
Journal:  J Cancer Res Clin Oncol       Date:  2003-03-07       Impact factor: 4.553

4.  A prognostic-factor risk index in advanced non-small-cell lung cancer treated with cisplatin-containing combination chemotherapy.

Authors:  T Shinkai; K Eguchi; Y Sasaki; T Tamura; Y Ohe; A Kojima; F Oshita; T Miya; H Okamoto; K Iemura
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

5.  Imaging features and prognostic value of 18F-FDG PET/CT detection of soft-tissue metastasis from lung cancer: a retrospective study.

Authors:  Tingting Xu; Xinyi Zhang; Shumao Zhang; Chunfeng Liu; Wenhui Fu; Chengrun Zeng; Yue Chen
Journal:  BMC Cancer       Date:  2020-06-26       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.